Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Human Immunoglobulins for intravenous use and hepatitis C viral transmission.

Human Immunoglobulins for intravenous use and hepatitis C viral transmission. Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more» Information about commercial reprint orders: http://cvi.asm.org/site/misc/reprints.xhtml To subscribe to to another ASM Journal go to: http://journals.asm.org/site/subscriptions/ CLINICAL AND DIAGNOSTiC LABORATORY IMMUNOLOGY, Nov. 1994, 1071-412X/94/$04.00+0 p. 613-619 Vol. 1, No. 6 Human Immunoglobulins for Intravenous Use and Hepatitis C Viral Transmissiont HERBERT B. SLADE* Clinical Research and Development, Department of Allerg/Immunology/AIDS, Rhone-Poulenc Rorer, Collegeville, Pennsylvania INTRODUCTION On February 23, 1994, a U.S. Food and Drug Administration (FDA)-licensed immunoglobulin intravenous (IGIV) manufacturer initiated a worldwide withdrawal of two products following an accumulation of 14 reported cases of hepatitis in American and European patients receiving one of these products. By July 1994, this number had grown to 112 in the United States alone (5). A newly licensed version of the product in question has since been introduced following the incorporation of a solvent-detergent treatment in the manufacturing process. This most recent episode has brought to light some unresolved questions concerning the past and future safety of IGIV products with respect to viral transmission in general and hepatitis C virus (HCV) in particular. HCV HCV is a small enveloped virus containing -10 kb of single-stranded RNA, with a http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical and Vaccine Immunology American Society For Microbiology

Human Immunoglobulins for intravenous use and hepatitis C viral transmission.

Clinical and Vaccine Immunology , Volume volume 1 (issue 6) – Nov 1, 1994

Human Immunoglobulins for intravenous use and hepatitis C viral transmission.

Clinical and Vaccine Immunology , Volume volume 1 (issue 6) – Nov 1, 1994

Abstract

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more» Information about commercial reprint orders: http://cvi.asm.org/site/misc/reprints.xhtml To subscribe to to another ASM Journal go to: http://journals.asm.org/site/subscriptions/ CLINICAL AND DIAGNOSTiC LABORATORY IMMUNOLOGY, Nov. 1994, 1071-412X/94/$04.00+0 p. 613-619 Vol. 1, No. 6 Human Immunoglobulins for Intravenous Use and Hepatitis C Viral Transmissiont HERBERT B. SLADE* Clinical Research and Development, Department of Allerg/Immunology/AIDS, Rhone-Poulenc Rorer, Collegeville, Pennsylvania INTRODUCTION On February 23, 1994, a U.S. Food and Drug Administration (FDA)-licensed immunoglobulin intravenous (IGIV) manufacturer initiated a worldwide withdrawal of two products following an accumulation of 14 reported cases of hepatitis in American and European patients receiving one of these products. By July 1994, this number had grown to 112 in the United States alone (5). A newly licensed version of the product in question has since been introduced following the incorporation of a solvent-detergent treatment in the manufacturing process. This most recent episode has brought to light some unresolved questions concerning the past and future safety of IGIV products with respect to viral transmission in general and hepatitis C virus (HCV) in particular. HCV HCV is a small enveloped virus containing -10 kb of single-stranded RNA, with a

Loading next page...
 
/lp/american-society-for-microbiology/human-immunoglobulins-for-intravenous-use-and-hepatitis-c-viral-mQGJUoNqC5

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Society For Microbiology
Copyright
Copyright © 1994 by the American society for Microbiology.
ISSN
1556-6811
eISSN
1556-679X
Publisher site
See Article on Publisher Site

Abstract

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more» Information about commercial reprint orders: http://cvi.asm.org/site/misc/reprints.xhtml To subscribe to to another ASM Journal go to: http://journals.asm.org/site/subscriptions/ CLINICAL AND DIAGNOSTiC LABORATORY IMMUNOLOGY, Nov. 1994, 1071-412X/94/$04.00+0 p. 613-619 Vol. 1, No. 6 Human Immunoglobulins for Intravenous Use and Hepatitis C Viral Transmissiont HERBERT B. SLADE* Clinical Research and Development, Department of Allerg/Immunology/AIDS, Rhone-Poulenc Rorer, Collegeville, Pennsylvania INTRODUCTION On February 23, 1994, a U.S. Food and Drug Administration (FDA)-licensed immunoglobulin intravenous (IGIV) manufacturer initiated a worldwide withdrawal of two products following an accumulation of 14 reported cases of hepatitis in American and European patients receiving one of these products. By July 1994, this number had grown to 112 in the United States alone (5). A newly licensed version of the product in question has since been introduced following the incorporation of a solvent-detergent treatment in the manufacturing process. This most recent episode has brought to light some unresolved questions concerning the past and future safety of IGIV products with respect to viral transmission in general and hepatitis C virus (HCV) in particular. HCV HCV is a small enveloped virus containing -10 kb of single-stranded RNA, with a

Journal

Clinical and Vaccine ImmunologyAmerican Society For Microbiology

Published: Nov 1, 1994

There are no references for this article.